Noninvasive biomarkers for lupus nephritis

Ting Liu,Yun-long Yang,Yan Zhou,Yong-mei Jiang
DOI: https://doi.org/10.1093/labmed/lmae015
IF: 1.865
2024-03-17
Laboratory Medicine
Abstract:Abstract Lupus nephritis (LN) is one of the most severe clinical manifestations of systemic lupus erythematosus (SLE). Notably, the clinical manifestations of LN are not always consistent with the histopathological findings. Therefore, the diagnosis and activity monitoring of this disease are challenging and largely depend on invasive renal biopsy. Renal biopsy has side effects and is associated with the risk of bleeding and infection. There is a growing interest in the development of novel noninvasive biomarkers for LN. In this review, we summarize most of the LN biomarkers discovered so far by correlating current knowledge with future perspectives. These biomarkers fundamentally reflect the biological processes of kidney damage and repair during disease. Furthermore, this review highlights the role of urinary cell phenotype detection in the diagnosis, monitoring, and treatment of LN and summarizes the limitations and countermeasures of this test.
medical laboratory technology
What problem does this paper attempt to address?
This paper aims to solve the problems of diagnosis and activity monitoring of lupus nephritis (LN), a severe clinical manifestation of systemic lupus erythematosus (SLE). Currently, the diagnosis of LN mainly depends on invasive renal biopsy, which has the risks of bleeding and infection and is not suitable for continuous monitoring of patients' conditions. Therefore, there is an urgent need to develop new non - invasive biomarkers to effectively reflect the activity and severity of LN. ### Core issues of the paper 1. **Improving diagnostic accuracy**: Existing conventional laboratory markers such as proteinuria, serum complement levels, and anti - double - stranded DNA antibodies have limitations in diagnosing renal injury or monitoring disease activity and cannot completely replace renal biopsy. The paper explores the application of new non - invasive biomarkers in early diagnosis and continuous monitoring to improve the accuracy and sensitivity of diagnosis. 2. **Reducing invasive examinations**: Renal biopsy is an invasive operation with high risks and complications. The paper studies non - invasive biomarkers in blood and urine, which can be obtained by non - invasive methods, significantly increase the frequency of renal injury assessment, assist in monitoring disease activity, and guide clinical treatment. 3. **Early intervention and prognosis evaluation**: Early diagnosis, continuous monitoring, and early intervention of LN are crucial for improving the prognosis of patients. The paper emphasizes the important role of non - invasive biomarkers in early diagnosis, monitoring disease activity, and guiding treatment. ### Main content - **Blood biomarkers**: including genes, cytokines, chemokines, autoantibodies, adhesion molecules, etc. For example, the HLA - DR15 haplotype is associated with diffuse proliferative glomerulonephritis; the levels of BLyS and IFNAR1 in serum are related to the frequency of LN. - **Urine biomarkers**: Urine contains various components, such as epithelial cells, proteins, glucose, inorganic salts, and trace elements, which can be used as biomarkers in laboratory medicine. The immunocyte phenotype in urine is related to renal interstitial infiltration, reflecting the activity of the disease and renal injury. Proteins in urine such as IL - 16 and TGF - β are also closely related to the activity of LN. - **Other potential biomarkers**: including urine ferritin/creatinine ratio (UFCR), neuropilin - 1 (NRP - 1), etc. These biomarkers are significantly elevated in LN patients and can be used for early diagnosis and prognosis evaluation. ### Conclusion The paper summarizes the currently discovered non - invasive biomarkers of LN and looks forward to future research directions. Compared with renal biopsy, non - invasive biomarkers have many advantages, such as simple operation, low risk, and suitability for continuous monitoring. However, these biomarkers still need further verification and optimization to improve their reliability and practicality in clinical applications.